IL161997A - Pharmaceutical composition comprising a 5ht1 receptor agonist - Google Patents

Pharmaceutical composition comprising a 5ht1 receptor agonist

Info

Publication number
IL161997A
IL161997A IL16199702A IL16199702A IL161997A IL 161997 A IL161997 A IL 161997A IL 16199702 A IL16199702 A IL 16199702A IL 16199702 A IL16199702 A IL 16199702A IL 161997 A IL161997 A IL 161997A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
receptor agonist
agonist
receptor
pharmaceutical
Prior art date
Application number
IL16199702A
Other languages
English (en)
Other versions
IL161997A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL161997A0 publication Critical patent/IL161997A0/xx
Publication of IL161997A publication Critical patent/IL161997A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
IL16199702A 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist IL161997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition
PCT/EP2002/013715 WO2003047552A2 (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Publications (2)

Publication Number Publication Date
IL161997A0 IL161997A0 (en) 2005-11-20
IL161997A true IL161997A (en) 2005-12-18

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16199702A IL161997A (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Country Status (29)

Country Link
US (1) US20050032867A1 (xx)
EP (2) EP1527773A1 (xx)
JP (1) JP3699969B2 (xx)
KR (1) KR100591237B1 (xx)
CN (1) CN1289069C (xx)
AR (1) AR037627A1 (xx)
AT (1) ATE291900T1 (xx)
AU (1) AU2002358602B2 (xx)
BR (1) BR0214497A (xx)
CA (1) CA2469019C (xx)
CO (1) CO5580741A2 (xx)
DE (1) DE60203537T2 (xx)
ES (1) ES2236608T3 (xx)
FI (1) FI20022128A (xx)
GB (1) GB0129117D0 (xx)
HK (1) HK1069111A1 (xx)
HU (1) HU229313B1 (xx)
IL (1) IL161997A (xx)
IS (1) IS2481B (xx)
MX (1) MXPA04005420A (xx)
MY (1) MY129314A (xx)
NO (1) NO329896B1 (xx)
NZ (1) NZ532829A (xx)
PL (1) PL194702B1 (xx)
PT (1) PT1450770E (xx)
RU (1) RU2285526C2 (xx)
TW (1) TWI240638B (xx)
WO (1) WO2003047552A2 (xx)
ZA (1) ZA200403849B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
BRPI0409127A (pt) * 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
CA2527368A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Pharmaceutical composition
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1954298A4 (en) * 2005-11-28 2012-10-31 Imaginot Pty Ltd DISPENSING SYSTEM FOR ORAL THERAPEUTIC CONNECTION
CN101431895A (zh) * 2006-05-01 2009-05-13 卡普里康制药公司 新颖的曲坦制剂和制备它们的方法
WO2008039358A2 (en) * 2006-09-30 2008-04-03 Capricorn Pharma Inc. Resin-complex granulation for water-soluble drugs and associated methods
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
WO1999043306A1 (en) * 1998-02-26 1999-09-02 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
CO5580741A2 (es) 2005-11-30
PL370669A1 (en) 2005-05-30
EP1450770A2 (en) 2004-09-01
EP1527773A1 (en) 2005-05-04
AU2002358602A1 (en) 2003-06-17
DE60203537D1 (de) 2005-05-04
JP2005515991A (ja) 2005-06-02
HUP0402178A3 (en) 2011-05-30
WO2003047552A2 (en) 2003-06-12
AR037627A1 (es) 2004-11-17
EP1450770B1 (en) 2005-03-30
RU2285526C2 (ru) 2006-10-20
WO2003047552A3 (en) 2003-09-25
JP3699969B2 (ja) 2005-09-28
ZA200403849B (en) 2005-10-26
FI20022128A0 (fi) 2002-12-03
GB0129117D0 (en) 2002-01-23
CA2469019A1 (en) 2003-06-12
PL194702B1 (pl) 2007-06-29
IS7293A (is) 2004-06-03
MXPA04005420A (es) 2004-10-11
DE60203537T2 (de) 2005-09-15
ATE291900T1 (de) 2005-04-15
TW200304384A (en) 2003-10-01
MY129314A (en) 2007-03-30
HU229313B1 (en) 2013-10-28
CA2469019C (en) 2005-09-13
US20050032867A1 (en) 2005-02-10
TWI240638B (en) 2005-10-01
FI20022128A (fi) 2003-06-06
CN1289069C (zh) 2006-12-13
PT1450770E (pt) 2005-08-31
ES2236608T3 (es) 2005-07-16
IL161997A0 (en) 2005-11-20
HUP0402178A2 (hu) 2005-02-28
KR100591237B1 (ko) 2006-06-19
IS2481B (is) 2008-12-15
NZ532829A (en) 2005-05-27
KR20050044720A (ko) 2005-05-12
HK1069111A1 (en) 2005-05-13
BR0214497A (pt) 2004-10-19
NO329896B1 (no) 2011-01-24
CN1610539A (zh) 2005-04-27
AU2002358602B2 (en) 2005-05-26
NO20025805D0 (no) 2002-12-03
RU2004120292A (ru) 2005-04-10
NO20025805L (no) 2003-06-06

Similar Documents

Publication Publication Date Title
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
AP2001002376A0 (en) Nmda receptor agonist pharmaceutical compositions
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
EP1385486A4 (en) NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
GB2394894B (en) New use for pharmaceutical composition
EP1411904A4 (en) PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
HUP0200057A3 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
IL160438A0 (en) Pharmaceutical compositions containing an angiotensin ii receptor antagonist
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
AU2002342940A8 (en) New pharmaceutical compounds
GB0130576D0 (en) Dopamine D1 receptor agonist pro-drug compounds & derivatives
GB0201849D0 (en) A�- adenosine receptor agonists
GB0201919D0 (en) A�-Adenosine receptor agonists
IL166080A0 (en) Sustained-release tablet composition comprising a dopamine receptor agonist
AU2002338040A1 (en) Receptor antagonist

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed